Anti-PDGF-B monoclonal antibody reduces liver fibrosis development
スポンサーリンク
概要
- 論文の詳細を見る
- 2010-11-01
著者
-
Shimada Hideaki
Inflammation Research Unit St. Louis Laboratories Pfizer Global Research And Development
-
Katragadda Madan
Asia Research Pfizer Worldwide Research And Development
-
Ochi Takashi
Discovery Biology Nagoya Laboratories Pfizer Global Research And Development
-
Nii Aisuke
Drug Safety Research & Development Nagoya Laboratories Pfizer Global Research And Development
-
Fujita Isami
Discovery Biology Nagoya Laboratories Pfizer Global Research And Development
-
Masferrer Jaime
Inflammation Research Unit St. Louis Laboratories Pfizer Global Research And Development
-
Ogawa Shinji
Inflammation Research Unit St. Louis Laboratories Pfizer Global Research And Development
-
INAGAKI Kazuyuki
Discovery Biology, Nagoya Laboratories, Pfizer Global Research and Development
-
MOFFAT Mark
Pharmaceutical Sciences, St. Louis Laboratories, Pfizer Global Research and Development
-
VIOLAND Bernard
Asia Research, Pfizer Worldwide Research and Development
-
ARCH Robert
Inflammation Research Unit, St. Louis Laboratories, Pfizer Global Research and Development
-
Arch Robert
Inflammation Research Unit St. Louis Laboratories Pfizer Global Research And Development
-
Moffat Mark
Pharmaceutical Sciences St. Louis Laboratories Pfizer Global Research And Development
-
Violand Bernard
Asia Research Pfizer Worldwide Research And Development
-
Inagaki Kazuyuki
Discovery Biology Nagoya Laboratories Pfizer Global Research And Development
関連論文
- Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A
- Erythroderma and Epidermal Necrosis Induced by a Type of Proton Pump Inhibitor in Beagle Dogs
- P8-47 Investigation of environmental influences on the behavioral observation of rats(BLOOD/TOXICOKINETICS/OTHERS-2)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- Anti-PDGF-B monoclonal antibody reduces liver fibrosis development
- Neuronal Necrosis in a Dog Following Exposure to an NMDA Receptor Antagonist